Mr. George Tziras reports

HELUS PHARMA APPOINTS FORMER PFIZER CHIEF MEDICAL OFFICER DR. FREDA LEWIS-HALL TO BOARD OF DIRECTORS & CHAIR OF THE SCIENTIFIC ADVISORY COMMITTEE

Helus Pharma (Cybin Inc.) has appointed Dr. Freda Lewis-Hall, DFAPA, MFPM, to its board of directors. Dr. Lewis-Hall will also serve as chair of the company's scientific advisory committee.

• In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus's novel serotonergic agonist (NSA) portfolio.

Dr. Lewis-Hall is a pioneering physician and biopharmaceutical executive with more than 40 years of experience spanning clinical care, research, academia, corporate leadership and public health advocacy. She began her medical career as a practicing psychiatrist, focusing on the impact of mental illness on families and communities.

She later held senior leadership roles across the biopharmaceutical industry, including serving for more than a decade on Pfizer's executive leadership team as executive vice-president and chief medical officer. In that role, she led a global medical organization operating in more than 125 countries and supporting a broad portfolio of medicines and vaccines. She subsequently served as chief patient officer, advancing patient engagement, inclusion and health equity initiatives across the enterprise. During her tenure, she also helped lead the spinout of SpringWorks Therapeutics and served on its board of directors, guiding the company through regulatory approvals and its evolution into a commercial-stage organization prior to its acquisition by Merck KGaA for approximately $3.4-billion. Dr. Lewis-Hall has also held senior leadership positions at Vertex Pharmaceuticals, Bristol Myers Squibb, Pharmacia Corp., Eli Lilly and company.

Dr. Lewis-Hall is a distinguished fellow of the American Psychiatric Association and previously served as vice-chairperson and associate professor in the department of psychiatry at Howard University College of Medicine. She has also advised the National Institute of Mental Health.

"Dr. Lewis-Hall is a highly respected physician and leader whose career has been defined by bringing complex, innovative therapies from development to patients around the world, particularly in areas of serious and underserved mental health need," said Michael Cola, chief executive officer of the company.

"Her deep experience in clinical strategy, regulatory engagement and global commercialization will be invaluable as we advance our novel serotonergic agonist programs for psychiatric disorders and continue building a company grounded in scientific rigor, patient impact and responsible scale. We are honoured to welcome her to our board and as chair overseeing the scientific advisory committee."

"Throughout my career, I have focused on ensuring that scientific innovation translates into therapies that make a meaningful difference for patients -- and that can be delivered reliably within real-world health care systems," said Dr. Lewis-Hall. "What distinguishes Helus Pharma is its disciplined approach at the intersection of rigorous science, a thoughtfully advancing clinical portfolio and focused execution in areas of significant unmet need in mental health. I believe the company is building a differentiated development platform that has yet to be fully recognized by the broader market."

She continues: "Helus Pharma's commitment to strong clinical design, reproducibility and regulatory clarity reflects the standards required to earn and sustain trust among patients, providers and regulators. This work is deeply personal to me, given my early experience on the front lines of mental health care. I look forward to supporting the company as it advances programs designed to deliver meaningful, durable outcomes for patients and long-term value for stakeholders."

As chair of the scientific advisory committee, Dr. Lewis-Hall will provide leadership in scientific, clinical and regulatory governance across Helus's portfolio, advising on discovery opportunities, clinical development strategy, and regulatory pathways to support pipeline advancement and progress toward commercialization.

As a member of the board of directors, she will contribute to corporate governance and long-term strategic oversight, helping ensure that patient outcomes, clinical rigor and disciplined decision-making remain central to the company's growth strategy.

Dr. Lewis-Hall's appointment to the company's board of directors is subject to approval of Cboe Canada.

About Helus Pharma (Cybin Inc.)

Helus Pharma, the commercial operating name of Cybin, is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs -- novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.

With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received breakthrough therapy designation from the United States Food and Drug Administration and HLP004, also a proprietary NSA in phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The company operates in Canada, the United States, the United Kingdom and Ireland.

We seek Safe Harbor.